Offspring Biosciences AB provides highly qualitative and reliable contract research services for molecular pathology-based analyses in tissues and cells.
The company, which sprung out of the now closed AstraZeneca R&D at Södertälje, was founded in July 2012 by Anders Dahlstrand, Dan Sunnemark and Anne Svensson, all former senior researchers with many years of experience supporting the local AZ organisation with molecular pathology-based analyses.
Offspring Biosciences provides advanced contract research services to customers primarily within the pharmaceutical industry. We deliver data which support decision making for successful and more cost-effective development of novel treatments of human diseases. The information targets key questions in pharmaceutical drug development such as the relevancy of the chosen drug targets, the drug binding properties, the effectiveness of the drug in preclinical treatment studies of mechanistic and pathology-associated biomarkers as well as safety liabilities and manifestations. In addition, we facilitate our customer’s translational research with comparative analyses between the human disease state and the corresponding preclinical models in animals and can provide support for development of ligands for PET imaging.
Although our experience is primarily from supporting pharmaceutical research targeting CNS disorders and chronic pain, our services are generic and our deliveries includes studies on behalf of projects targeting a range of disease states, such as:
- Alzheimer’s disease
- Huntington’s disease
- Parkinson’s disease
- Multiple sclerosis
- Chronic pain states
We have access to laboratory facilities, fully equipped to support the above-mentioned services, at the Biovation Park (formerly owned by AstraZeneca R&D).